Dec 20,2021
According to the Implementation Opinions on Promoting the Project of "Jiangxi Produces Excellent Products" (GGQXXXXXXJZ [2021] No. 31) and the Notice on Carrying out the First Selection of "Jiangxi Produces Excellent Products" (GGXXJZ [2021] No. 176), 136 products were determined to be the first "Jiangxi Produces Excellent Products" after enterprise application, recommendation by local competent departments, qualification review, expert review, seeking department opinions and publicity, and are now published.
Dec 20,2021
The first press conference of "Jiangxi produces high-quality products" was held in Nanchang
On the morning of December 16, the first Jiangxi Provincial Press Conference on "Jiangxi Produces High quality Products" was held in Nanchang with the theme of "High end Manufacturing: Jiangxi Produces High quality Products". Zheng Zhengchun, a member of the Party Leadership Group and Deputy Director of the Department of Industry and Information Technology of Jiangxi Province, attended and introduced the first "Jiangxi Produces Fine Products". Gong Hong, director of the Science and Technology Department of the Provincial Department of Industry and Information Technology, Zhao Shanshan, deputy director of the Quality Development Bureau of the Provincial Market Supervision Bureau, and Chen Jinwen, president of the Provincial Institute of Industry and Information Technology, attended the conference and answered questions from reporters. The press conference was hosted by Xu Cheng, Deputy Director of the External Information Department of the Publicity Department of the Provincial Party Committee.
Dec 15,2021
Promote win-win development and integrate into the bridgehead of Daya Bay District
From November 26 to 30, 2021, a group of 7 people from Shenzhen Hi tech Investment Group Co., Ltd. Talent Equity Investment Fund Management Co., Ltd. and 2 people from Shenzhen Huayuhengtai Commercial Factoring Co., Ltd. accompanied by Jing Yue, vice chairman of the company, came to the company to carry out investment research, accompanied by the company's investors and board representatives.
Nov 27,2021
Sidelights of Jiangxi Biological Reading Launching Meeting
With a long history of five thousand years, it has nurtured profound national culture, and has a long history of experience with Chinese characteristics. It is an enduring treasure in the management of cultural arts. It is like the stars in summer, shining with dazzling brilliance, and it is like flowers in spring, emitting a fragrant fragrance. When we quietly open a book and wander in the sea of books, knowledge accompanies us in every step of our life. This is our own desire of enterprise managers and the sincere desire of the company's talent growth.
At 16:00 p.m. on November 2, 2021, the company's mid-level reading kick-off meeting was held in front of the office building lobby, and more than 30 senior executives and people at or above the middle and grassroots level participated in the kick-off meeting. First of all, the office introduced the goal and significance of this reading meeting in detail. In order to enable the company's managers to correctly understand their roles and do a good job in positioning themselves, according to the relevant requirements of the Notice on Further Strengthening the Company's Management issued by the company, the company organized the first reading conference in November. The current learning content is "Management's Role Cognition and Positioning".
Nov 26,2021
Measures for the Administration of the Batch Issuance of Biological Products
Article 1 In order to strengthen the supervision and administration of biological products, regulate the approval and issuance of biological products, and ensure the safety and effectiveness of biological products, these Measures are formulated in accordance with the relevant provisions of the Pharmaceutical Administration Law of the People's Republic of China (hereinafter referred to as the Pharmaceutical Administration Law) and the Vaccine Administration Law of the People's Republic of China (hereinafter referred to as the Vaccine Administration Law).
Article 2 The term "batch issuance of biological products" as mentioned in these Measures refers to the activities of the SDA to review and inspect the vaccine products, blood products, in vitro diagnostic reagents for blood source screening and other biological products specified by the SDA that have been approved for marketing, and to issue batch issuance certificates to those that meet the requirements before each batch of products is marketed or imported.